治疗大疱性表皮松解症：给药是关键。

相似文献

1

Therapies for epidermolysis bullosa: delivery is key.

Br J Dermatol. 2019 Jan;180(1):17-19. doi: 10.1111/bjd.17324.

2

Evaluating a Targeted Cancer Therapy Approach Mediated by RNA -Splicing In Vitro and in a Xenograft Model for Epidermolysis Bullosa-Associated Skin Cancer.

Int J Mol Sci. 2022 Jan 5;23(1):575. doi: 10.3390/ijms23010575.

3

Epidermolysis bullosa in Northern Ireland.

Br J Dermatol. 1992 Oct;127(4):318-21. doi: 10.1111/j.1365-2133.1992.tb00448.x.

4

Eye Involvement and Management in Inherited Epidermolysis Bullosa.

Drugs. 2022 Aug;82(12):1277-1285. doi: 10.1007/s40265-022-01770-8. Epub 2022 Sep 8.

5

Inherited and acquired blistering diseases.

N Engl J Med. 1992 Jul 16;327(3):196-7. doi: 10.1056/NEJM199207163270312.

6

High concordance between clinical diagnosis of epidermolysis bullosa and immunofluorescence with a small, well-matched antibody panel.

Australas J Dermatol. 2018 Feb;59(1):73-76. doi: 10.1111/ajd.12665. Epub 2017 Jul 13.

7

[Syndromes 13. Epidermolysis bullosa].

Ned Tijdschr Tandheelkd. 1999 Aug;106(8):302-5.

8

[Immunofluorescence mapping for diagnosis of congenital epidermolysis bullosa].

Actas Dermosifiliogr. 2010 Oct;101(8):673-82.

9

[Nutritional condition of epidermolysis bullosa patients assessed from body height and weight].

Nihon Hifuka Gakkai Zasshi. 1990 Jun;100(7):805-9.

10

Epidermolysis bullosa: pathophysiology and nursing care.

Neonatal Netw. 2004 Nov-Dec;23(6):25-32. doi: 10.1891/0730-0832.23.6.25.

引用本文的文献

1

Innovations in the Treatment of Dystrophic Epidermolysis Bullosa (DEB): Current Landscape and Prospects.

Ther Clin Risk Manag. 2023 Jun 14;19:455-473. doi: 10.2147/TCRM.S386923. eCollection 2023.

本文引用的文献

1

An ex vivo RNA trans-splicing strategy to correct human generalized severe epidermolysis bullosa simplex.

Br J Dermatol. 2019 Jan;180(1):141-148. doi: 10.1111/bjd.17075. Epub 2018 Oct 7.

2

Non-viral gene delivery systems: hurdles for bench-to-bedside transformation.

Pharmazie. 2017 Nov 1;72(11):627-693. doi: 10.1691/ph.2017.7092.

3

Genome editing for the reproduction and remedy of human diseases in mice.

J Hum Genet. 2018 Feb;63(2):107-113. doi: 10.1038/s10038-017-0360-4. Epub 2017 Nov 27.

4

The Promise and Challenge of In Vivo Delivery for Genome Therapeutics.

ACS Chem Biol. 2018 Feb 16;13(2):376-382. doi: 10.1021/acschembio.7b00680. Epub 2017 Oct 19.

5

Advances in the delivery of RNA therapeutics: from concept to clinical reality.

Genome Med. 2017 Jun 27;9(1):60. doi: 10.1186/s13073-017-0450-0.

6

RNA-based therapies for genodermatoses.

Exp Dermatol. 2017 Jan;26(1):3-10. doi: 10.1111/exd.13141.

7

Nucleic Acids Delivery Systems: A Challenge for Pharmaceutical Technologists.

Curr Drug Metab. 2015;16(1):3-16. doi: 10.2174/1389200216666150401110211.

8

Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification.

J Am Acad Dermatol. 2014 Jun;70(6):1103-26. doi: 10.1016/j.jaad.2014.01.903. Epub 2014 Mar 29.

9

K14 mRNA reprogramming for dominant epidermolysis bullosa simplex.

Hum Mol Genet. 2010 Dec 1;19(23):4715-25. doi: 10.1093/hmg/ddq405. Epub 2010 Sep 22.

Therapies for epidermolysis bullosa: delivery is key.

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献